Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 plus recombinant human endostatin with IMRT in elderly patients with locally advanced head and neck cancer
ChiCTR-OIC-17013043Phase 2Recruiting
- Sponsor
- Tumor Hospital Affiliated to Guizhou Medical University
- Start
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur and endostar in head and neck cancer (HNC), nasopharyngeal carcinoma (NPC) and head and neck squamous cell carcinoma (HNSCC), sponsored by Tumor Hospital Affiliated to Guizhou Medical University. Primary endpoints: EORTC Quality of Life Measurement Scale, Observation of acute toxicity of neoadjuvant chemotherapy and 1 more. Started Oct 2016; status: recruiting.
02
Drugs
tegafurendostar
03
Conditions
head and neck cancer (HNC)nasopharyngeal carcinoma (NPC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR-OIC-17013043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17013043.